Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06283459 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
A Phase 1 study, sponsored by Imunon.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06283459 is a Phase 1 study that has completed, run by Imunon. The registered enrollment target is 24 participants.
The verdict
NCT06283459, a Phase 1 study, has completed, sponsored by Imunon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365).
Interventions
- BIOLOGICAL IMNN-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2025-03-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06283459
The ClinicalTrials.gov registry entry for NCT06283459 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imunon, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMNN-101 is the first listed.
NCT06283459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06283459 about?
NCT06283459 is a clinical study titled "Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2". This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365).
What is the current status of trial NCT06283459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-06-04. Estimated completion is 2025-03-07.
What interventions are being tested in trial NCT06283459?
The interventions under investigation include: IMNN-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06283459?
This trial is sponsored by Imunon, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.